{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/tinzaparin",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023324",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023324_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   acalabrutinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023325",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023325_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  aceclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023325_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"aceclofenac\" outputclass=\"int-drug\">aceclofenac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   aceclofenac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aceclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023326",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023326_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">acenocoumarol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  acenocoumarol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023327",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023327_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023328",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023328_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   alprostadil   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023329",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023329_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"alteplase\" outputclass=\"int-drug\">alteplase</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  alteplase  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023330",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023330_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023331",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023331_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   anagrelide   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023332",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023332_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"andexanet alfa\" outputclass=\"int-drug\">Andexanet alfa</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">affect</ph> <ph outputclass=\"int-parameter\">the anticoagulant effect of</ph> <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Andexanet alfa   is predicted to   affect   the anticoagulant effect of   tinzaparin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Andexanet alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023333",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023333_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"apixaban\" outputclass=\"int-drug\">apixaban</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  apixaban  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023334",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023334_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"argatroban\" outputclass=\"int-drug\">argatroban</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  argatroban  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023335",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023335_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   aspirin   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023336",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023336_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   axitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023337",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023337_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023338",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023338_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"benzydamine\" outputclass=\"int-drug\">benzydamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   benzydamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Benzydamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023339",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023339_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   bevacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023340",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023340_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"bismuth\" outputclass=\"int-drug\">Bismuth</ph> <ph outputclass=\"int-substanceQualifier\">subsalicylate</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Bismuth   subsalicylate   is predicted to   increase   the risk of bleeding events when given with   tinzaparin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bismuth</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023341",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023341_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">bivalirudin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  bivalirudin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023342",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023342_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   bosutinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023343",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023343_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bromfenac\" outputclass=\"int-drug\">bromfenac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   bromfenac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bromfenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023344",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023344_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   cabozantinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023345",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023345_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023346",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023346_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   cangrelor   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023347",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023347_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"caplacizumab\" outputclass=\"int-drug\">caplacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   caplacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Caplacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023348",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023348_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023349",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023349_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  celecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023349_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"celecoxib\" outputclass=\"int-drug\">celecoxib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   celecoxib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Celecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023350",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023350_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023351",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023351_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   cilostazol   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023352",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023352_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   citalopram   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023353",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023353_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   clopidogrel   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023354",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023354_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cobimetinib\" outputclass=\"int-drug\">cobimetinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   cobimetinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobimetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023355",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023355_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">dabigatran</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  dabigatran  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023356",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023356_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">danaparoid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  danaparoid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023357",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023357_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   dapoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023358",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023358_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023359",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023359_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   dasatinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023360",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023360_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  dexketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023360_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dexketoprofen\" outputclass=\"int-drug\">dexketoprofen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   dexketoprofen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023361",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023361_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  diclofenac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023361_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"diclofenac\" outputclass=\"int-drug\">diclofenac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   diclofenac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Diclofenac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023362",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023362_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   dipyridamole   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023363",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023363_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023364",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023364_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   duloxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023365",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023365_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">edoxaban</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  edoxaban  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023366",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023366_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"eicosapentaenoic acid\" outputclass=\"int-drug\">eicosapentaenoic acid</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   eicosapentaenoic acid   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eicosapentaenoic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023367",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023367_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023368",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023368_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023369",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023369_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023370",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023370_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023371",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023371_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023372",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023372_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   epoprostenol   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023373",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023373_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023374",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023374_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">eptifibatide</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  eptifibatide  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023375",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023375_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   escitalopram   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023376",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023376_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  etodolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023376_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etodolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023377",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023377_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  etoricoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023377_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etoricoxib\" outputclass=\"int-drug\">etoricoxib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   etoricoxib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoricoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023378",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023378_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   fluoxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023379",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023379_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  flurbiprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023379_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"flurbiprofen\" outputclass=\"int-drug\">flurbiprofen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   flurbiprofen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Flurbiprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023380",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023380_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   fluvoxamine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023381",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023381_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">fondaparinux</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  fondaparinux  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023382",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023382_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"heparin\" outputclass=\"int-drug\">heparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  heparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023382_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"heparin\" outputclass=\"int-drug\">heparin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  tinzaparin  and  heparin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023383",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023383_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ibrutinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023384",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023384_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  ibuprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023384_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ibuprofen\" outputclass=\"int-drug\">ibuprofen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ibuprofen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibuprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023385",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023385_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   iloprost   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023386",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023386_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   imatinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023387",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023387_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023388",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023388_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  indometacin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023388_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"indometacin\" outputclass=\"int-drug\">indometacin</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   indometacin   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indometacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023389",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023389_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   inotersen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023390",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023390_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023391",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023391_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  ketoprofen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023391_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ketoprofen\" outputclass=\"int-drug\">ketoprofen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ketoprofen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketoprofen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023392",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023392_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  ketorolac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023392_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ketorolac\" outputclass=\"int-drug\">ketorolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ketorolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ketorolac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023393",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023393_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   lenvatinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023394",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023394_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023395",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023395_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023396",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023396_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  mefenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023396_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"mefenamic acid\" outputclass=\"int-drug\">mefenamic acid</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   mefenamic acid   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mefenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023397",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023397_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  meloxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023397_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"meloxicam\" outputclass=\"int-drug\">meloxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   meloxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Meloxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023398",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023398_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  nabumetone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023398_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"nabumetone\" outputclass=\"int-drug\">nabumetone</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   nabumetone   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nabumetone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023399",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023399_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  naproxen  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023399_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"naproxen\" outputclass=\"int-drug\">naproxen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   naproxen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Naproxen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023400",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023400_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">nicotinic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  nicotinic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023401",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023401_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   nintedanib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023402",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023402_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023403",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023403_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">omega-3-acid ethyl esters</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   omega-3-acid ethyl esters   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023404",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023404_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  parecoxib  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023404_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"parecoxib\" outputclass=\"int-drug\">parecoxib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   parecoxib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Parecoxib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023405",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023405_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   paroxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023406",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023406_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   pazopanib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023407",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023407_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023408",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023408_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  phenazone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023408_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"phenazone\" outputclass=\"int-drug\">phenazone</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   phenazone   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023409",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023409_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"phenindione\" outputclass=\"int-drug\">phenindione</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  phenindione  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023410",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023410_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  piroxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023410_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"piroxicam\" outputclass=\"int-drug\">piroxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   piroxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Piroxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023411",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023411_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ponatinib\" outputclass=\"int-drug\">ponatinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ponatinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023412",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023412_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023413",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023413_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023414",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023414_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023415",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023415_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   prasugrel   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023416",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023416_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023417",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023417_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023418",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023418_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"ranibizumab\" outputclass=\"int-drug\">Ranibizumab</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of bleeding events when given with</ph> <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Ranibizumab   increases   the risk of bleeding events when given with   tinzaparin .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ranibizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023419",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023419_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   regorafenib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023420",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023420_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">rivaroxaban</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  rivaroxaban  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023421",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023421_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023422",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023422_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   sertraline   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023423",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023423_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   sorafenib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023424",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023424_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023425",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023425_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">streptokinase</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  streptokinase  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023426",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023426_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  sulindac  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023426_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"sulindac\" outputclass=\"int-drug\">sulindac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   sulindac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulindac</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023427",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023427_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   sunitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023428",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023428_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023429",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023429_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023430",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023430_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">tenecteplase</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tenecteplase  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023431",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023431_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tenoxicam  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023431_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"tenoxicam\" outputclass=\"int-drug\">tenoxicam</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   tenoxicam   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenoxicam</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023432",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023432_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tiaprofenic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023432_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"tiaprofenic acid\" outputclass=\"int-drug\">tiaprofenic acid</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   tiaprofenic acid   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tiaprofenic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023433",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023433_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   ticagrelor   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023434",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023434_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">tirofiban</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tirofiban  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023435",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023435_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tolfenamic acid  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023435_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"tolfenamic acid\" outputclass=\"int-drug\">tolfenamic acid</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   tolfenamic acid   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolfenamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023436",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023436_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023437",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023437_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   trametinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023438",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023438_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023439",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023439_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   trastuzumab emtansine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023440",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023440_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   treprostinil   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023441",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023441_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023442",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023442_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023443",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023443_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"urokinase\" outputclass=\"int-drug\">urokinase</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  urokinase  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023444",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023444_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023445",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023445_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   venlafaxine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023446",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023446_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"volanesorsen\" outputclass=\"int-drug\">volanesorsen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid depending on platelet countconsult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   volanesorsen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises avoid depending on platelet countconsult product literature .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Volanesorsen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023447",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023447_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   vortioxetine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023448",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/tinzaparin#bnf_i1643858023448_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"tinzaparin\" outputclass=\"int-heading-drug\">tinzaparin</ph> and <ph otherprops=\"warfarin\" outputclass=\"int-drug\">warfarin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  tinzaparin  and  warfarin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				}
			],
			"hasSearchLabel": " Tinzaparin  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/tinzaparin.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Tinzaparin </title>"
			},
			"rdfs:label": "tinzaparin"
		}
	]
}